Impaired glucose tolerance: who and how treats it?
Pre-diabetes includes impaired glucose tolerance (IGT) and fasting hyperglycemia. According to epidemiologic data, the number of ITG patience is twice as high as the number of diabetes mellitus (DM) patients. Cardiovascular event (CVE) risk in IGT patients is by 1.32 times higher than that in normog...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1027 |
| Summary: | Pre-diabetes includes impaired glucose tolerance (IGT) and fasting hyperglycemia. According to epidemiologic data, the number of ITG patience is twice as high as the number of diabetes mellitus (DM) patients. Cardiovascular event (CVE) risk in IGT patients is by 1.32 times higher than that in normoglycemic individuals. IGT is one of the 5 metabolic syndrome components. The crucial task of IGT management is postprandial hyperglycemia control. Together with lifestyle modification, three groups of antihyperglycemic agents are used: acarbose, metformin, and thiazolidines. Acarbose locally inhibits α-glucosidase, an intestinal enzyme, and prevent glucose absorption at the early digestion stages. According to the results of STOP-NIDDM and APREL trials, acarbose is a medication of choice in treating IGT patients. IGT diagnostics and treatment are among priority areas of modern cardiology |
|---|---|
| ISSN: | 1728-8800 2619-0125 |